project . 2017 - 2022 . On going

TILC

Targeting Innate Lymphoid Cells
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 694502 Call for proposal: ERC-2015-AdG
  • Funded under: H2020 | ERC | ERC-ADG Overall Budget: 2,500,000 EURFunder Contribution: 2,500,000 EUR
  • Status: On going
  • Start Date
    01 Jan 2017
    End Date
    31 Dec 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
TILC focuses on Innate Lymphoid Cells (ILCs). ILCs are a newly discovered type of lymphocyte, and their study opens up new perspectives for understanding and manipulating of immunity. ILCs include cytotoxic ILCs (NK cells) and helper-like ILCs (ILC1, ILC2 & ILC3). Studies of ILC2 cells have advanced considerably, but much remains unknown about the respective roles of NK, ILC1 and ILC3 cells. TILC aims to explore new frontiers in ILC biology, by focusing on these subsets of ILCs in mice and humans, through five specific aims. 1. NK cells, ILC1 & NCR+ILC3 are known to express NKp46 in humans and mice, but the nature of the NKp46 ligands remains unclear, limiting o...
Partners
Description
TILC focuses on Innate Lymphoid Cells (ILCs). ILCs are a newly discovered type of lymphocyte, and their study opens up new perspectives for understanding and manipulating of immunity. ILCs include cytotoxic ILCs (NK cells) and helper-like ILCs (ILC1, ILC2 & ILC3). Studies of ILC2 cells have advanced considerably, but much remains unknown about the respective roles of NK, ILC1 and ILC3 cells. TILC aims to explore new frontiers in ILC biology, by focusing on these subsets of ILCs in mice and humans, through five specific aims. 1. NK cells, ILC1 & NCR+ILC3 are known to express NKp46 in humans and mice, but the nature of the NKp46 ligands remains unclear, limiting o...
Partners
Any information missing or wrong?Report an Issue